Omiganan Phase II Rosacea Study Demonstrates Promising Results

Armen Hareyan's picture

MIGENIX has been notified by its partner for the dermatologic applications of omiganan, Cutanea Life Sciences, that a recently completed Phase II rosacea study has demonstrated:

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.